Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MMP10 | P09238 | 5/20 | 0.39 |
| ▸ | MMP8 | P22894 | 5/20 | 0.39 |
| ▸ | CALCA | P06881 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087546 | 0.94 | MMP13 (0.42) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6093967 | 0.92 | MMP13 (0.47) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6086557 | 0.90 | MMP13 (0.42) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL5309519 | 0.89 | MAPK8 (0.42) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6089345 | 0.88 | MMP13 (0.39) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6087562 | 0.88 | KCNH2 (0.50) | KCNE1CCR1KCNQ1KCNH2CYP2C9 | |
| SCHEMBL6086385 | 0.88 | MMP13 (0.39) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6094348 | 0.88 | MMP13 (0.44) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6095011 | 0.88 | MMP13 (0.44) | MMP13KCNE1CCR1KCNQ1KCNH2 | |
| SCHEMBL6093733 | 0.88 | SOS1 (0.47) | MMP13KCNE1CCR1KCNQ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | claimed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | claimed |
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261322-A1 | HIV integrase inhibitors | TYMP, PAICS, TYMS | MMP13 4089/4885KCNE1 3346/4885CCR1 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.